Dislipemia del síndrome metabólico. Documento sumario del Foro-HDL

Referencias bibliográficas

• Adeli K, Taghibiglou C, Van Iderstine SC, Lewis GF. Mechanisms of hepatic very low-density lipoprotein overproduction in insulin resistance. Trends Cardiovasc Med. 2001;11:170-6.
• American Diabetes Association. Standards of Medical Care in Diabetes. Diabetes Care. 2005;28 Suppl 1:S4-36.
• American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2004;27 Suppl 1:S15-35.
• Assman G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10 year follow-up of the prospective cardiovascular Munster (PROCAM) Study .Circulation. 2002;105:310-5.
• Athyros VG, Papageorgiu AA, Athyrou VU, Demitradis DS, Kontopoulos AG. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined ghyperlipidaemia. Diabetes Care. 2002;25:1198-2002.
• Athyros VG, Papageorgiu AA, Hatzikonstandinou HA, Didangelos TP, Carina MV, Kranitsas DF, et al. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia. Am J Cardiol. 1997;80: 608-13.
• Ballantyne CM, Blazing MA, Hunninghake DB, Davidson MH, Yuan Z, DeLucca P, et al. Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: results of the Comparative HDL Efficacy and Safety Study (CHESS). Am Heart J. 2003;146:862-9.
• Ballantyne CM, Pazzucconi F, Pintó X, Reckless JP, Stein E, McKenney J, et al. Efficacy and tolerability of fluvastatin extended-release delivery system: a pooled analysis. Clin Ther. 2001;23:177-92.
• Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med. 2004;350:1505-9.
• Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, et al; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-500.
• Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al; CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685-96.
• DAIS Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet. 2001;357: 905-10.
• Davidson MH. Emerging therapeutic strategies for the management of dyslipidemia in patients with the metabolic syndrome. Am J Cardiol. 2004;93 Suppl:C3-11.
• De Backer G, Ambriosini E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al; Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J. 2003;24:1601-10.
• DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14:173-94.
• Desprès JP, Moorjani S, Lupien PJ, Tremblay A, Bouchard C. Regional distribution of body fat, plasma lipoproteins and cardiovascular disease. Arteriosclerosis. 1990;10:497-511.
• Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005;112:2725-34.
• Downs JR, Clearfield M, Weis S, Whitney E, Saphiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA. 1998;279:1615-22.
• Duez H, Fruchart JC, Staels B. PPARs ininflammation, atherosclerosis and thrombosis. J Cardiovasc Risk. 2001;8:187-94.
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summery of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and treatment of High Blood Cholesterol in Adults (Adults Treatment Panel III). JAMA. 2001;285:2486-96.
• Farnier M, Freeman MW, Macdonell G, Perevozskaya I, Davies MJ, Mitchel YB, et al; the Ezetimibe Study Group. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. Eur Heart J. 2005;26:897-905.
• Farnier M, Salko T, Isaacsohn JL, Troendle AJ, Dejager S, Gonasun L. Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin + fibrate (bezafibrate, fenofibrate, or gemfibrozil). Am J Cardiol. 2003;92:794-7.
• Golay A, Zech L, Shi MZ, Chiou YA, Reaven GM, Chen YD. High density lipoprotein (HDL) metabolism in noninsulin-dependent diabetes mellitus: measurement of HDL turnover using tritiated HDL. J Clin Endocrinol Metab. 1987;65:512-8.
• González Santos P, González Alegre T, Valdivielso Felices P. HDL, triglicéridos y síndrome de resistencia a la insulina. Clin Invest Arterioscler. 2001;13 Supl 4:27-34.
• Gotto AM. Contemporary diagnosis and management of lipid disorders. Handbooks in Health Care. Pennsylvania: AMM Co; 2001.
• Gray RS, Robbins DC, Wang W, Yeh JL, Fabsitz RR, Cowan LD, et al. Relation of LDL size to the insulin resistance syndrome and coronary heart disease in American Indians. The Strong Heart Study. Arterioscler Thromb Vasc Biol. 1997;17:2713-20.
• Grundy SM, Hansen B, Smith SC, Cleeman JI, Kahn RA, for conference participants. Clinical Management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Asociation conference on scientific issues related to management. Circulation. 2004;109:551-6.
• Grundy SM, Vega GL, McGovern ME, Tulloch BR, Kendall DM, Fitz-Patrick D, et al; Diabetes Multicenter Research Group. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med. 2002;162:1568-76.
• Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet. 1999;354:447-55.
• Haffner SM, Fong D, Hazuda HP, Pugh JA, Patterson JK. Hyperinsulinemia, upper body adiposity, and cardiovascular risk factors in non-diabetics. Metabolism. 1988;37:338-45.
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
• Herman WH, Hoerger TJ, Brandle M, Hicks K, Sorensen S, Zhang P, et al; Diabetes Prevention Program Research Group. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med. 2005;142:323-32.
• Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, et al; STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol. 2003;92:152-60.
• Karpe F, Tornwall P, Olivecrona T, Steiner G, Carlson LA, Hamsten A. Composition of human low density lipoprotein: effects of postprandial triglyceride-rich lipoproteins, lipoprotein lipase, hepatic lipase and cholesteryl ester transfer protein. Atherosclerosis. 1993;98:33-49.
• Krauss RM, Eckel RH, Howard B, Appel LJ, Daniels SR, Deckelbaum RJ, et al. AHA dietary guidelines: revision 2000: a statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Circulation. 2000;102:2284-99.
• Kyrklund C, Backman JT, Neuvonen M, Neuvonen PJ. Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin Pharmacol Ther. 2003;73:538-44.
• Lamarche B, Tchernof AG, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation. 1997;95:69-75.
• Larosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-35.
• Lebovitz HE. Insulin resistance: definition and consequences. Exp Clin Endocrinol Diabetes. 2001;109 Suppl 2:S135-48.
• Malik J, Melenovsky V, Wichterle D, Haas T, Simek J, Ceska R, et al. Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial - FAT). Cardiovasc Res. 2001;52:290-8.
• Manninen V, Elo MO, Frick MH, Haapa K, Heinonen OP, Heinsalmi P, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA. 1988; 260:641-51.
• Miller DB, Spence JD. Clinical pharmacokinetics of fibric acid deivatives (fibrates). Clin Pharmacokinet. 1998;34:155-62.
• Moghadasian MH, Frohlich JJ. Effects of dietary phytosterols on cholesterol metabolism and atherosclerosis: clinical and experimental evidence. Am J Med. 1999;107:588-94.
• Pauciullo P, Borgnino C, Paoletti R, Mariani M, Mancini M. Efficay and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidemia (FACT study). Atherosclerosis. 2000;150;429-36.
• Pihlajamaki J, Gylling H, Miettinen TA, Laakso M. Insulin resistance is associated with increased cholesterol synthesis and decreased cholesterol absorption in normoglycemic men. J Lipid Res. 2004;45:507-12.
• Pintó X, Meco JF. Tratamiento de la dislipemia diabética con fármacos hipolipemiantes. Nuevos conceptos. Clin Invest Arterioscler. 2004;16:160-9.
• Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988;37:1595-607.
• Robins SJ, Rubins HB, Faas FH, Schaefer EJ, Elam MB, Anderson JW, et al; Veterans Affairs HDL Intervention Trial (VA-HIT). Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). Diabetes Care. 2003;26:1513-7.
• Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341: 410-830.
• Rubins HB, Robins SJ, Collins D, Nelson DB, Elam MB, Schaefer EJ, et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med. 2002;162:2597-604.
• Sacks EM, Pfeffer MA, Moye LA, Rouleau JL, Rhuterford JD, Cole TG, et al. The effects of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-9.
• Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, et al; DASH-Sodium Collaborative Research Group, for the DASH-sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med. 2001;344:3-10.
• Scandinavian Simvastatin Survival Study Group (4S). Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study. Lancet. 1994;344:1383-9.
• Scott CL. Diagnosis, prevention, and intervention for the metabolic syndrome. Am J Cardiol. 2003;92 Suppl:i35-42.
• Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149-58.
• Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301-7.
• Shepherd TJ, Cobbe SM, Ford I, Isles CG, Lorimer AR, McFarlane PW, et al. Prevention of coronary heart disease with pravastatin men with hypercholesterolaemia. N Engl J Med. 1995;333:1301-7.
• Smith SC Jr, Blair SN, Bonow RO, Brass LM, Cerqueira MD, Dracup K, et al. AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol. 2001;38:1581-3.
• Snow V, Aronson MD, Hornbake ER, Mottur-Pilson C, Weiss KB; Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Lipid control in the management of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2004;140:644-9.
• Stalenhoef AFH, Ballantyne CM, Tuomilehto J, et al. Comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study. Diabetologia. 2004;47 Suppl 1: A409-10.
• Steiner G. Fibrates in the metabolic syndrome and in diabetes. Endocrinol Metab Clin North Am. 2004;33:545-55.
• Sung KC, Hwang ST. Association between insulin resistance and apolipoprotein B in normoglycemic Koreans. Atherosclerosis. 2005;180:161-9.
• Taghibiglou C, Rashid-Kolvear F, Van Iderstine SC, Le-Tien H, Fantus IG, Lewis GF, et al. Hepatic very-low density lipoprotein-apo B overproduction in associated with attenuated hepatic insulin signalling and overexpression of protein-tyrosine phosphatase 1B in a fructose-fed hamster model of insulin resistance. J Biol Chem. 2002;277:793-803.
• Tall AR, Yvan-Charvet L, Wang N. The failure of torcetrapib. Whas it the molecule or the mechanism. Arterioscler Thromb Vasc Biol. 2007;27:257-60.
• Taskinen MR. Diabetic dyslipidemia. Atheroscler Suppl. 2002;3: 47-51.
• Taskinen MR. Lipoprotein lipase in diabetes. Diabetes Metab Rev. 1987;3:551-70.
• Tato F, Vega GL, Grundy SM. Determinants of plasma HDL-cholesterol in hypertriglyceridemic patients: role of colesterol-ester-transfer protein and lecithin cholesteryl acyl transferase. Arterioscler Tromb Vasc Biol. 1997;17:56-63.
• Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. 2004;110:3512-7.
• Tenenbaum A, Motro M, Fisman EZ, Tanne D, Boyko V, Behar S. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med. 2005;165: 1154-60.
• The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-57.
• Vaughan CJ, Gotto AM Jr. Update on statins: 2003. Circulation. 2004;110:886-92.
• Winkler K, Ablestshauser C, Hoffmann MM, Friedrich I, Baumstark MW, Wieland H, et al. Effect of fluvastatin slow release on low density lipoprotein (LDL) subfractions in patients with type 2 diabetes mellitus: baseline LDL profile determines specific mode of action. J Clin Endocrinol Metab. 2002;87:5485-90.
• Zavaroni I, Dall'Aglio E, Alpi O, Bruschi F, Bonora E, Pezzarossa A, et al. Evidence for an independent relationship between plasma insulin and concentration of high density lipoprotein cholesterol and triglyceride. Atherosclerosis. 1985;55:259-66.